ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO308

A Serum Magnesium Concentration Lower Than 2 mg/dL Predicts Mortality in CKD Patients: A Propensity Score-Matching Study

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Rodelo-Haad, Cristian, University Hospital Reina Sofia, Córdoba, Spain
  • Santamaria, Rafael, University Hospital Reina Sofia, Córdoba, Spain
  • López-López, Isabel, University Hospital Reina Sofia, Córdoba, Spain
  • Pendon-Ruiz de Mier, Victoria, University Hospital Reina Sofia, Córdoba, Spain
  • Peregrin, Cayetana Moyano, University Hospital Reina Sofia, Córdoba, Spain
  • Ojeda lopez, Raquel, University Hospital Reina Sofia, Córdoba, Spain
  • Rodriguez, Mariano, University Hospital Reina Sofia, Córdoba, Spain
  • Munoz-Castaneda, Juan R., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
  • Martin-Malo, Alejandro, University Hospital Reina Sofia, Córdoba, Spain
  • Soriano, Sagrario, University Hospital Reina Sofia, Córdoba, Spain
Background

Decreased serum mg may be associated with mortality and vascular calcifications. There is limited information on the impact of low mg (mg) in CKD stage 4 patients. We aimed to evaluate whether serum mg levels are associated with mortality in a matched population of CKD patients.

Methods

Patients were stratified into tertiles according to serum mg (T1<2.0 mg/dl, T2 =2.01-2.39 mg/dl and T3>2.4 mg/dl). For survival analysis, we used log-rank tests to compare Kaplan–Meier (KM) probability of death curves and performed uni- and multivariable Cox regression analysis. Given the comparable survival among T2 and T3 patients, serum mg <> 2 mg/dl was used to further perform propensity score matching (PSM) to minimize potential confounding and selection biases within tertiles. We used the derived propensity scores to match the groups in a 1:1 ratio. Further, KM analysis with the matched population was performed.

Results

This study included 1002 patients evaluated in the advanced-CKD outpatient clinic from 2009 to 2018. During the study follow-up, 158 died, 84 from T1, 34 from T2, and 35 from T3. Furthermore, 616 patients started dialysis, whereas 242 remained under follow-up in the outpatient clinic. KM showed that patients from T1 had a worse survival as compared with T2 and T3 (p<0.001; Figure 1A). Multivariate Cox proportional hazard showed that patients with mg <2 mg/dl had a higher mortality risk (HR 1.61, CI 1.05—2.46) as compared to the other groups. After matching, it was obtained an adjusted population of 343 patients with mg <2 mg/dl and 343 with higher concentrations of mg. Survival analysis with PSM-adjusted cohorts showed that patients with mg <2 mg/dl had worse survival compared to T2 and T3 (log-rank p=0.01; HR 1.73, CI 1.02—2.36, p=0.44; Figure 1B)

Conclusion

In appropriately-matched patients, a serum mg <2 mg/dl predicts mortality.

Figure 1. Survival analysis of not matched cohorts (A) and PSM-adjusted cohorts (B).

Funding

  • Government Support - Non-U.S.